- Cytokinetics (NASDAQ:CYTK) has announced that Servier has elected to terminate the sublicense agreement between Amgen for the development and commercialization of omecamtiv mecarbil in Europe and the Commonwealth of Independent States, including Russia. The termination is effective as of March 18, 2021
- Recently Amgen terminated the Collaboration and Option Agreement between Amgen and Cytokinetics effective May 20, 2021. Given Servier’s notice to Amgen, all worldwide rights related to the development and commercialization of omecamtiv mecarbil will now return to Cytokinetics on that date.
- In October, data from GALACTIC-HF Phase 3 trial of omecamtiv mecarbil showed that the study met primary composite endpoint of reduction in heart failure events or cardiovascular death. Additional data presented at American Heart Association Scientific meet showed that death from cardiovascular causes occurred in 19.6% patients treated with omecamtiv mecarbil and 19.4% assigned to placebo.
Cytokinetics gets rights to omecamtiv mecarbil after pact terminations
Recommended For You
About CYTK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CYTK | - | - |
Cytokinetics, Incorporated |